What is Heron Therapeuti (HRTX) stock price today?

Heron Therapeuti (HRTX) currently trades at $1.19 per share. The stock has a market capitalization of $224.36M and a P/E ratio of —x.

Is HRTX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Heron Therapeuti has a Smart Value Score of 25/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Heron Therapeuti's revenue and earnings?

Heron Therapeuti has trailing twelve-month (TTM) revenue of $154.90M with profit margins of -13.00%. Earnings per share (EPS) is $-0.12.

Is HRTX stock overvalued or undervalued?

Based on our DCF model, Heron Therapeuti's intrinsic value is $3.52, representing a margin of safety of 66.76%. The stock currently trades at a P/E of —x.

HRTX

Heron Therapeuti

NASDAQ: HRTX · HEALTHCARE · BIOTECHNOLOGY

$1.19

-1.65% today

Updated 2026-04-29

Market cap

$224.36M

P/E ratio

—

P/S ratio

1.45x

EPS (TTM)

$-0.12

Dividend yield

—

52W range

$1 – $3

Volume

2.1M

Market cap

$224.36M

P/E ratio

—

P/S ratio

1.45x

EPS (TTM)

$-0.12

Dividend yield

—

52W range

$1 – $3

Volume

2.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.7

Growth

5.0

Quality

C+

2.5

Profitability

6.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$4.33

+264.12%

12-Month target

—

Intrinsic (DCF)

$3.52

Margin of safety

+66.76%

1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ 66.76% below intrinsic value

Risks

- Thin margins at -13.00%

- Negative free cash flow $-9.18M

- Revenue declining -0.50% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$107.67M	$127.04M	$144.28M	$154.90M	$154.90M
Net income	$-134.52M	$-110.56M	$-13.58M	$-20.20M	$-2.95M
EPS	—	—	—	—	$-0.12
Free cash flow	$-148.74M	$-60.33M	$-24.23M	$-27.91M	$-9.18M
Profit margin	-124.93%	-87.02%	-9.41%	-13.04%	-13.00%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
HRTX	$224.36M	25	4.7	2.5	6.7	5.0	+66.76%	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Heron Therapeuti trades at $1.19. Our Smart Value Score of 25/100 indicates the stock is weak. TTM revenue stands at $154.90M. with profit margins at -13.00%. Our DCF model estimates intrinsic value at $3.52.

Frequently asked questions

What is Heron Therapeuti's stock price?

Heron Therapeuti (HRTX) trades at $1.19.

Is Heron Therapeuti overvalued?

Smart Value Score 25/100 (Grade F, Strong Sell). DCF value $3.52.

What is the price target of Heron Therapeuti (HRTX)?

The analyst target price is $4.33, representing +264.1% upside from the current price of $1.19.

What is the intrinsic value of Heron Therapeuti (HRTX)?

Based on our DCF model, intrinsic value is $3.52, a +66.8% margin of safety versus $1.19.

What is Heron Therapeuti's revenue?

TTM revenue is $154.90M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio1.45x

ROE-2,409.00%

Beta1.42

50D MA$0.97

200D MA$1.26

Shares out0.19B

Float0.13B

Short ratio—

Avg volume2.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

HRTX vs LLY →HRTX vs JNJ →HRTX vs ABBV →Stock screener →